SCHEMBL17119252

SCHEMBL17119252

NC1=N[C@@](c2cc(NC(=O)c3ccc(F)cn3)ccc2F)(C(F)F)C[C@@H](CF)O1

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 0.66
CYP2D6 P10635 1/20 0.61
BACE2 Q9Y5Z0 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17119313 0.90 BACE1 (0.71) BACE1CYP2D6
SCHEMBL17119154 0.90 BACE1 (0.71) BACE1CYP2D6
SCHEMBL17119141 0.88 BACE1 (0.79) BACE1CYP2D6BACE2
SCHEMBL17119132 0.87 BACE1 (0.67) BACE1BACE2
SCHEMBL17119253 0.84 BACE1 (0.65) BACE1
SCHEMBL17119316 0.82 BACE1 (0.69) BACE1CYP2D6BACE2
SCHEMBL17119087 0.81 BACE1 (0.79) BACE1BACE2
SCHEMBL17119177 0.81 BACE1 (0.64) BACE1CYP2D6BACE2
SCHEMBL18707432 0.81 BACE1 (0.79) BACE1BACE2
SCHEMBL17119147 0.80 BACE1 (0.72) BACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758513-B2 Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity SHIONOGI & CO., LTD. (JP) 2017-09-12 US disclosed
US-20170008881-A1 DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2017-01-12 US disclosed
US-9540359-B2 Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity SHIONOGI & CO., LTD. (JP) 2017-01-10 US disclosed
US-20150266865-A1 DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266865-A1 DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, APP, BACE2 BACE1 1/4885CYP2D6 1534/4885BACE2 3/4885
US-20170008881-A1 DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, APP, BACE2 BACE1 1/4885CYP2D6 1534/4885BACE2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.